Autophagic Regulation of p62 is Critical for Cancer Therapy

Sequestosome1 (p62/SQSTM 1) is a multidomain protein that interacts with the autophagy machinery as a key adaptor of target cargo. It interacts with phagophores through the LC3-interacting (LIR) domain and with the ubiquitinated protein aggregates through the ubiquitin-associated domain (UBA) domain...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2018-05, Vol.19 (5), p.1405
Main Authors: Islam, Md Ariful, Sooro, Mopa Alina, Zhang, Pinghu
Format: Article
Language:English
Subjects:
Apoptosis
Autophagy
Cancer
Cancer therapies
Inclusion bodies
p62
PB1
Phagocytosis
Proteins
Review
self-oligomerization
therapy
Ubiquitin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sequestosome1 (p62/SQSTM 1) is a multidomain protein that interacts with the autophagy machinery as a key adaptor of target cargo. It interacts with phagophores through the LC3-interacting (LIR) domain and with the ubiquitinated protein aggregates through the ubiquitin-associated domain (UBA) domain. It sequesters the target cargo into inclusion bodies by its PB1 domain. This protein is further the central hub that interacts with several key signaling proteins. Emerging evidence implicates p62 in the induction of multiple cellular oncogenic transformations. Indeed, p62 upregulation and/or reduced degradation have been implicated in tumor formation, cancer promotion as well as in resistance to therapy. It has been established that the process of autophagy regulates the levels of p62. Autophagy-dependent apoptotic activity of p62 is recently being reported. It is evident that p62 plays a critical role in both autophagy and apoptosis. Therefore in this review we discuss the role of p62 in autophagy, apoptosis and cancer through its different domains and outline the importance of modulating cellular levels of p62 in cancer therapeutics.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms19051405